Willis-Knighton Health System
Internal Medicine residency · Shreveport, LA · Program website
Some matches pending. 5 people are awaiting a decision between possible publication profiles, so these numbers may change.
Trainees here publish more than most: 40% have published during training (1st of 31 internal medicine residencies with complete rosters), at 0.8 papers per trainee-year (13th), and they're first author on 26% of their papers. How trainees publish ↓
- 0
- Faculty
- 30
- Trainees
- 57
- Papers
- 40%
- Trainees published
- 0.81
- Papers / trainee-year
- 26%
- First author
Papers
By this program's faculty and trainees since 2022, 57 in all · 35 with a trainee author. Updated 2026-11-07.
- Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐AnalysisAbdulkareem M. Jomaa et al. · Diabetes Obesity and Metabolism · 2026 · PubMed
- TCT-859 Perioperative Amino Acid Infusion and Renal Outcomes in Cardiac Surgery: An Updated Meta-Analysis of Randomized Controlled TrialsMalik Saad Hayat et al. · Journal of the American College of Cardiology · 2026
- Disseminated Rhizomucor Miehei With Hemorrhagic StrokeHamza Aljarrah et al. · Infectious Diseases in Clinical Practice · 2026
- S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysisAbdulkareem M. Jomaa et al. · Journal of Gastroenterology · 2026 · PubMed
- POSTER: AML-1662: Racial Disparities in Outcomes Among Patients With NPM1-Mutated Acute Myeloid Leukemia: A Propensity Matched Real-World AnalysisHema Hotchandani et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
- ABCL-818: Synchronous Gray Zone Lymphoma and Colon Adenocarcinoma: A Diagnostic and Therapeutic ChallengeKashish Shah et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
- POSTER: AML-1665: Racial and Demographic Factors Associated With Allogenic Stem Cell Transplant Outcomes in Acute Myeloid Leukemia: A Propensity Score–Matched AnalysisIndraneel Abhijit Deshmukh et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
- POSTER: AML-520: Myelodysplasia-Related Mutation Clearance Is Associated With Improved Outcomes in Newly Diagnosed Acute Myeloid Leukemia Treated With Low-Intensity TherapyNaszrin Arani et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
- POSTER: AML-1672: Racial Disparities in Outcomes Among Patients With TP53-Mutated Acute Myeloid Leukemia: A Propensity-Matched Real-World AnalysisHema Hotchandani et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
- POSTER: CT-1643: Temporal Patterns of Infectious Complications Following BCMA-Directed CAR-T Therapy in Multiple Myeloma: A Propensity-Matched Real-World AnalysisHema Hotchandani et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
How trainees publishauthor positions, faculty co-authorship, ranks
Papers by current residents and fellows, and alumni within two years, published during training. Based on 12 of 30 trainees matched to publication records. Trainees with no match count as not yet published, so these figures are a floor.
Faculty detailsh-index, papers and author positions per person
Program leadership from the program's own pages, matched to publications. Leadership is mostly clinician-educators, so these numbers describe the teaching team, not the department's research. Works since 2022-01-01.
| Name | Research topics | h (lifetime) | Works | 1st | Last | Median FWCI |
|---|
30 trainees are counted above but never listed by name.
About Willis-Knighton Cancer Centerinstitution-wide internal medicine research
Internal Medicine publications from Willis-Knighton Cancer Center and affiliated institutions, since 2022. Updated 2026-11-07; refreshed daily.
Works per year · * 2026 so far
Internal Medicine research topics at Willis-Knighton Cancer Center
Papers in the window; each links to the list on OpenAlex.
Most cited at Willis-Knighton Cancer Center since 2024
All internal medicine papers there on OpenAlex
- Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro et al. · The Lancet · 2025 · PubMed · cited 333
- Radiotherapy vs Surgery for Survival and Locoregional Control of Head and Neck Extramedullary PlasmacytomaSrivatsa Surya Vasudevan et al. · JAMA Otolaryngology–Head & Neck Surgery · 2024 · PubMed · cited 13
- Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS StudyMinesh P. Mehta et al. · International Journal of Radiation Oncology*Biology*Physics · 2025 · PubMed · cited 10
- Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysisYing L. Liu et al. · Cancer · 2025 · PubMed · cited 10
- Management recommendations for kidney transplantation in patients with plasma cell dyscrasiaNaoka Murakami et al. · Kidney International · 2025 · PubMed · cited 9
- A non-interventional cardiologist’s guide to coronary chronic total occlusionsLindsey A. Cilia et al. · Frontiers in Cardiovascular Medicine · 2024 · PubMed · cited 5
- Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp TrialElizabeth A. Hahn et al. · International Journal of Radiation Oncology*Biology*Physics · 2024 · PubMed · cited 4
- Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapyMatthew A. Powell et al. · International Journal of Gynecological Cancer · 2026 · PubMed · cited 3
- A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107)Angeles Alvarez Secord et al. · International Journal of Gynecological Cancer · 2025 · cited 2
- Clinical Outcomes After Proton Therapy Reirradiation for Recurrent Malignant Glioma: Analysis From the Prospective Proton Collaborative Group RegistryOmer Gal et al. · Advances in Radiation Oncology · 2025 · PubMed · cited 2